# Daratumumab Versus Control Treatment: A Systematic Review and Meta-analysis Study of Survival Outcomes Among Multiple Myeloma Patients: Survival Outcomes of Multiple Myeloma Treatment with Daratumumab

## TL;DR

This study finds that Daratumumab improves survival outcomes for multiple myeloma patients across different treatment groups.

## Contribution

A meta-analysis showing Daratumumab's consistent efficacy in multiple myeloma subgroups, including relapsed and newly diagnosed patients.

## Key findings

- Daratumumab significantly improved overall response rates and MRD negativity across all subgroups.
- Progression or death risk was lower in the Daratumumab group compared to controls.
- Efficacy was consistent in relapsed, transplant-eligible, and transplant-ineligible patient groups.

## Abstract

This meta-analysis aimed to evaluate the efficacy of Daratumumab compared to
control treatments in multiple myeloma across subgroups, including relapsed
or refractory (RRMM), newly diagnosed transplant-eligible (ND/ESCT), and
transplant-ineligible (ND/ISCT) patients.

A comprehensive literature search was conducted across PubMed, Scopus, and
Web of Science. Randomized controlled trials and comparative studies
evaluating Daratumumab versus control treatments in multiple myeloma
patients were included. A random-effects model was employed to calculate
pooled effect estimates of overall response rate (ORR), progression or death
(PRD), minimum residual disease (MRD) negativity, and mortality.

The analysis included data from 35 studies, 21 studies (n=7,604 patients) in
the RRMM subgroup, 12 studies (n=10,216 patients) in the ND/ISCT subgroup,
and 6 studies (n=4,619 patients) in the ND/ESCT subgroup, comprising 22,439
patients (including healthy controls). Daratumumab significantly improved
ORR (OR: 2.58, 95% CI: 2.26–2.93, P0.01) and MRD negativity rates across all
subgroups. PRD risk was lower in the Daratumumab group (RD: -0.14, 95% CI:
-0.16 to -0.12), with consistent efficacy across RRMM, ND/ESCT, and ND/ISCT
patients.

This meta-analysis confirms Daratumumab's significant efficacy across
multiple patient subgroups, providing broad clinical benefits in multiple
myeloma treatment. While some heterogeneity and potential publication bias
were observed, Daratumumab remains a robust therapeutic option for extending
progression-free and overall survival.